Table 4. Influence of AEs on the completion of neoadjuvant therapy.

Treatment plan adjustment	Patients (n=21)
Dose reduction due to AEs, n (%)
Pyrotinib	6 (28.6)
Trastuzumab	0
Albumin-bound paclitaxel	0
Treatment interruption due to AEs, n (%)
Pyrotinib†	11 (52.4)
Treatment delay due to AEs‡, n (%)
Trastuzumab	7 (33.3)
Albumin-bound paclitaxel	8 (38.1)

^†, the median cumulative interruption time of pyrotinib was 7 days (range, 1–24 days); ^‡, these delays were considered to be related to AEs caused by weekly albumin-bound paclitaxel treatment. AEs, adverse events.